Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease
Article first published online: 27 DEC 2012
Copyright © 2013 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 65, Issue 1, pages 186–196, January 2013
How to Cite
Drouin, E. E., Seward, R. J., Strle, K., McHugh, G., Katchar, K., Londoño, D., Yao, C., Costello, C. E. and Steere, A. C. (2013), A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis & Rheumatism, 65: 186–196. doi: 10.1002/art.37732
- Issue published online: 27 DEC 2012
- Article first published online: 27 DEC 2012
- Accepted manuscript online: 8 OCT 2012 12:11PM EST
- Manuscript Accepted: 27 SEP 2012
- Manuscript Received: 28 MAY 2012
- NIH. Grant Numbers: AR-20358, P41-GM-104603/RR-10888, S10-RR-15942, S10-RR-20946, contracts N01-HV-28178, N01-HV-00239
- Dana Foundation
- Mathers Foundation
- English, Bonter, Mitchell Foundation
- Eshe Fund
- Lyme/Arthritis Research Fund
- Massachusetts General Hospital
- Arthritis Foundation
- Walter J. and Lille A. Berbecker Foundation
- Lillian B. Davey Foundation
Autoantigen presentation by HLA–DR molecules is thought to be a central component of many autoimmune diseases, but identifying disease-relevant autoantigens has been a difficult challenge. In this study we aimed to identify autoantigens in patients with antibiotic-refractory Lyme arthritis, in which infection-induced autoimmunity is thought to play an important role.
Using tandem mass spectrometry, naturally presented HLA–DR self peptides from a patient's synovium were identified, synthesized, and reacted with his peripheral blood mononuclear cells (PBMCs). Immunoreactive peptides and their source proteins were then tested for T and B cell responses using large numbers of patient cells or sera.
Of 120 HLA–DR–presented self peptides identified from one patient, one peptide derived from endothelial cell growth factor (ECGF) caused his PBMCs to proliferate. T and B cell responses to ECGF occurred systemically in ∼10–30% of patients with early or late manifestations of Lyme disease, primarily in those with refractory arthritis–associated HLA–DR alleles, such as DRB1*0101 and 0401. Compared with patients with antibiotic-responsive arthritis, those with antibiotic-refractory arthritis had significantly higher concentrations of ECGF in synovial fluid (P < 0.0001) and more often had ECGF antibody reactivity. Among non–antibiotic-treated historical patients who developed arthritis, 26% had ECGF reactivity, which often developed before the onset of arthritis and was associated with significantly longer courses of arthritis.
T and B cell responses to ECGF occur in a subset of patients with Lyme disease, particularly in those with antibiotic-refractory arthritis, providing the first direct evidence of autoimmune T and B cell responses in this illness.